Based on these considerations, there might be a potential therapeutic strategy for the development of adjuvant treatment for MDD by targeting the inflammatory pathways mediated by pro- and anti-inflammatory cytokines, including IL-12 and IL-4, which needs further investigation. This evidence concerns the gene IL4 and major depressive disorder.